Investigating therapies in ependymoma

References

• Bailey P, Cushing H. A classification of the tumors of the glioma group on a histogenetic basis with a correlated study on prognosis. Philadelphia (PA): JB lippincott; 1926.
   Google Scholar
• Lehman NL. Central nervous system tumors with ependymal features: a broadened spectrum of primarily ependymal differentiation? J Neuropathol Exp Neurol. 2008;67:177–188.
   PubMed Web of Science ®Google Scholar
• CBTRUS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011 [Internet]. 2015. [cited 2016 Mar 6]. Available from: www.cbtrus.org/reports/reports.html
   Google Scholar
• McGuire CS, Sainani KL, Fisher PG. Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg. 2009;110:725–729.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD. The 2007 WHO classification of tumors of the central nervous system. Lyon (France): IARC Press; 2007.
   Google Scholar
• Raghunathan A, Wani K, Armstrong TS, et al. Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathol Zurich Switz. 2013;23:584–594.
   PubMed Web of Science ®Google Scholar
• Tihan T, Zhou T, Holmes E, et al. The prognostic value of histological grading of posterior fossa ependymomas in children: a Children’s Oncology Group study and a review of prognostic factors. Mod Pathol. 2008;21:165–177.
   PubMed Web of Science ®Google Scholar
• Ellison DW, Kocak M, Figarella-Branger D, et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed. 2011;10:7.
   PubMedGoogle Scholar
• Armstrong TS, Vera-Bolanos E, Bekele BN, et al. Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro Oncol. 2010;12:862–870.
   PubMed Web of Science ®Google Scholar
• Pica A, Miller R, Villa S, et al. The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network. Int J Radiat Oncol Biol Phys. 2009;74:1114–1120.
   PubMed Web of Science ®Google Scholar
• Rushing EJ, Cooper PB, Quezado M, et al. Subependymoma revisited: clinicopathological evaluation of 83 cases. J Neurooncol. 2007;85:297–305.
   PubMed Web of Science ®Google Scholar
• Sarkar C, Mukhopadhyay S, Ralte AM, et al. Intramedullary subependymoma of the spinal cord: a case report and review of literature. Clin Neurol Neurosurg. 2003;106:64–69.
   Web of Science ®Google Scholar
• Yuh EL, Barkovich AJ, Gupta N. Imaging of ependymomas: MRI and CT. Childs Nerv Syst. 2009;25:1203–1213.
   PubMed Web of Science ®Google Scholar
• Jaremko JL, Jans LB, Coleman LT, et al. Value and limitations of diffusion-weighted imaging in grading and diagnosis of pediatric posterior fossa tumors. AJNR Am J Neuroradiol. 2010;31:1613–1616.
   PubMed Web of Science ®Google Scholar
• Engelhard HH, Villano JL, Porter KR, et al. Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina. J Neurosurg Spine. 2010;13:67–77.
   PubMed Web of Science ®Google Scholar
• Paulino AC, Wen B-C, Buatti JM, et al. Intracranial ependymomas: an analysis of prognostic factors and patterns of failure. Am J Clin Oncol. 2002;25:117–122.
   PubMed Web of Science ®Google Scholar
• McLaughlin MP, Marcus RB Jr, Buatti JM, et al. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys. 1998;40:845–850.
   PubMed Web of Science ®Google Scholar
• Schild SE, Nisi K, Scheithauer BW, et al. The results of radiotherapy for ependymomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1998;42:953–958.
   PubMed Web of Science ®Google Scholar
• Margetis K, Koutsarnakis C, Stranjalis G. Primary cerebellar myxopapillary ependymoma. J Neurooncol. 2011;104:839–840.
   PubMed Web of Science ®Google Scholar
• Idowu MO, Rosenblum MK, Wei XJ, et al. Ependymomas of the central nervous system and adult extra-axial ependymomas are morphologically and immunohistochemically distinct–a comparative study with assessment of ovarian carcinomas for expression of glial fibrillary acidic protein. Am J Surg Pathol. 2008;32:710–718.
   PubMed Web of Science ®Google Scholar
• McGuire CS, Sainani KL, Fisher PG. Both location and age predict survival in ependymoma: a SEER study. Pediatr Blood Cancer. 2009;52:65–69.
   PubMed Web of Science ®Google Scholar
• Rodriguez D, Cheung MC, Housri N, et al. Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the surveillance, epidemiology, and end results (SEER) database (1973-2005). J Surg Res. 2009;156:340–351.
   PubMed Web of Science ®Google Scholar
• Merchant TE, Li C, Xiong X, et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol. 2009;10:258–266.
   PubMed Web of Science ®Google Scholar
• Guyotat J, Metellus P, Giorgi R, et al. Infratentorial ependymomas: prognostic factors and outcome analysis in a multi-center retrospective series of 106 adult patients. Acta Neurochir Wien. 2009;151:947–960.
   PubMed Web of Science ®Google Scholar
• Koshy M, Rich S, Merchant TE, et al. Post-operative radiation improves survival in children younger than 3 years with intracranial ependymoma. J Neurooncol. 2011;105:583–590.
   PubMed Web of Science ®Google Scholar
• Combs SE, Kelter V, Welzel T, et al. Influence of radiotherapy treatment concept on the outcome of patients with localized ependymomas. Int J Radiat Oncol Biol Phys. 2008;71:972–978.
   PubMed Web of Science ®Google Scholar
• Rogers L, Pueschel J, Spetzler R, et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas? J Neurosurg. 2005;102:629–636.
   PubMed Web of Science ®Google Scholar
• Venkatramani R, Dhall G, Patel M, et al. Supratentorial ependymoma in children: to observe or to treat following gross total resection? Pediatr Blood Cancer. 2011;58:380–383.
   PubMed Web of Science ®Google Scholar
• Amirian ES, Armstrong TS, Gilbert MR, et al. Predictors of survival among older adults with ependymoma. J Neurooncol. 2012;107:183–189.
   PubMed Web of Science ®Google Scholar
• Swanson EL, Amdur RJ, Morris CG, et al. Intracranial ependymomas treated with radiotherapy: long-term results from a single institution. J Neurooncol. 2011;102:451–457.
   PubMed Web of Science ®Google Scholar
• MacDonald SM, Safai S, Trofimov A, et al. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys. 2008;71:979–986.
   PubMed Web of Science ®Google Scholar
• Gunther JR, Sato M, Chintagumpala M, et al. Imaging changes in pediatric intracranial ependymoma patients treated with proton beam radiation therapy compared to intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;93:54–63.
   PubMed Web of Science ®Google Scholar
• Brown AP, Barney CL, Grosshans DR, et al. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys. 2013;86:277–284.
   PubMed Web of Science ®Google Scholar
• Conklin HM, Li C, Xiong X, et al. Predicting change in academic abilities after conformal radiation therapy for localized ependymoma. J Clin Oncol. 2008;26:3965–3970.
   PubMed Web of Science ®Google Scholar
• Grundy RG, Wilne SA, Weston CL, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol. 2007;8:696–705.
   PubMed Web of Science ®Google Scholar
• Zacharoulis S, Levy A, Chi SN, et al. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer. 2007;49:34–40.
   PubMed Web of Science ®Google Scholar
• Kano H, Yang HC, Kondziolka D, et al. Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas. J Neurosurg Pediatr. 2010;6:417–423.
   PubMed Web of Science ®Google Scholar
• Sangra M, Thorp N, May P, et al. Management strategies for recurrent ependymoma in the paediatric population. Childs Nerv Syst. 2009;25:1283–1291.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Etoposide for recurrent spinal cord ependymoma. Neurology. 2002;58:1310–1311.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Johnston SK. Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma. Cancer. 2009;115:4775–4782.
   PubMed Web of Science ®Google Scholar
• Rudà R, Bosa C, Magistrello M, et al. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. Neuro-Oncol. 2016;18:261–268.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.
   PubMed Web of Science ®Google Scholar
• Koos B, Peetz-Dienhart S, Riesmeier B, et al. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas. Neuropathol Appl Neurobiol. 2011;36:356–358.
   Web of Science ®Google Scholar
• Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004–1011.
   PubMed Web of Science ®Google Scholar
• Meco D, Servidei T, Lamorte G, et al. Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models. Neuro-Oncol. 2014;16:1067–1077.
   PubMed Web of Science ®Google Scholar
• Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol. 2010;11:871–879.
   PubMed Web of Science ®Google Scholar
• Lassaletta A, Lopez-Ibor B, Mateos E, et al. Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors. J Neurooncol. 2009;95:65–69.
   PubMed Web of Science ®Google Scholar
• Gammon DC, Bhatt MS, Tran L, et al. Intrathecal topotecan in adult patients with neoplastic meningitis. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 2006;63:2083–2086.
   PubMed Web of Science ®Google Scholar
• Halvorsen CM, Kolstad F, Hald J, et al. Long-term outcome after resection of intraspinal ependymomas: report of 86 consecutive cases. Neurosurgery. 2010;67:1622–1631; discussion 1631.
   PubMed Web of Science ®Google Scholar
• Plotkin SR, O’Donnell CC, Curry WT, et al. Spinal ependymomas in neurofibromatosis type 2: a retrospective analysis of 55 patients. J Neurosurg Spine. 2011;14:543–547.
   PubMed Web of Science ®Google Scholar
• Akyurek S, Chang EL, Yu TK, et al. Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center. J Neurooncol. 2006;80:177–183.
   PubMed Web of Science ®Google Scholar
• Weber DC, Wang Y, Miller R, et al. Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. Neuro-Oncol. 2015;17:588–595.
   PubMed Web of Science ®Google Scholar
• Vera-Bolanos E, Aldape K, Yuan Y, et al. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-Oncol. 2015;17:440–447.
   PubMed Web of Science ®Google Scholar
• Von Hoff K, Kieffer V, Habrand J-L, et al. Impairment of intellectual functions after surgery and posterior fossa irradiation in children with ependymoma is related to age and neurologic complications. BMC Cancer. 2008;8:15.
   PubMed Web of Science ®Google Scholar
• Walbert T, Mendoza TR, Vera-Bolaños E, et al. Symptoms and socio-economic impact of ependymoma on adult patients: results of the adult ependymoma outcomes project 2. J Neurooncol. 2015;121:341–348.
   PubMed Web of Science ®Google Scholar
• Armstrong TS, Vera-Bolanos E, Gilbert MR. Clinical course of adult patients with ependymoma: results of the adult ependymoma outcomes project. Cancer. 2011;117:5133–5141.
   PubMed Web of Science ®Google Scholar
• Modena P, Lualdi E, Facchinetti F, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol. 2006;24:5223–5233.
   PubMed Web of Science ®Google Scholar
• Korshunov A, Witt H, Hielscher T, et al. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol. 2010;28:3182–3190.
   PubMed Web of Science ®Google Scholar
• Puget S, Grill J, Valent A, et al. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol. 2009;27:1884–1892.
   PubMed Web of Science ®Google Scholar
• Mendrzyk F, Korshunov A, Benner A, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res. 2006;12:2070–2079.
   PubMed Web of Science ®Google Scholar
• Wani K, Armstrong TS, Vera-Bolanos E, et al. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol. 2012;123(5):727–738.
   PubMed Web of Science ®Google Scholar
• Kilday J-P, Mitra B, Domerg C, et al. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children’s Cancer Leukaemia Group (CCLG), Societe Francaise d’Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:2001–2011.
   Web of Science ®Google Scholar
• Rickert CH, Korshunov A, Paulus W. Chromosomal imbalances in clear cell ependymomas. Mod Pathol. 2006;19:958–962.
   PubMed Web of Science ®Google Scholar
• Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011;20:143–157.
   PubMed Web of Science ®Google Scholar
• Taylor MD, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell. 2005;8:323–335.
   PubMed Web of Science ®Google Scholar
• Johnson RA, Wright KD, Poppleton H, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature. 2010;466:632–636.
   PubMed Web of Science ®Google Scholar
• Pajtler KW, Witt H, Sill M, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015;27:728–743.
   PubMed Web of Science ®Google Scholar
• Archer TC, Pomeroy SL. Defining the molecular landscape of ependymomas. Cancer Cell. 2015;27:613–615.
   PubMed Web of Science ®Google Scholar
• Mack SC, Witt H, Piro RM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 2014;506:445–450.
   PubMed Web of Science ®Google Scholar
• Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510–522.
   PubMed Web of Science ®Google Scholar
• Parker M, Mohankumar KM, Punchihewa C, et al. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature. 2014;506:451–455.
   PubMed Web of Science ®Google Scholar
• Senetta R, Miracco C, Lanzafame S, et al. Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes. Neuro Oncol. 2011;13:176–183.
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ, Bentley L, Hernan R, et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res. 2002;8:3054–3064.
   PubMed Web of Science ®Google Scholar
• Gilbert M, Yuan Y, Wani K, et al. A phase II study of lapatinib and dose-dense temozolomide (TMZ) for adults with recurrent ependymoma: a CERN clinical trial. Neuro-Oncol. 2014;16:v13.
   Google Scholar
• Wagemakers M, Sie M, Hoving EW, et al. Tumor vessel biology in pediatric intracranial ependymoma. J Neurosurg Pediatr. 2010;5:335–341.
   PubMed Web of Science ®Google Scholar
• Green RM, Cloughesy TF, Stupp R, et al. Bevacizumab for recurrent ependymoma. Neurology. 2009;73:1677–1680.
   PubMed Web of Science ®Google Scholar
• DeWire M, Fouladi M, Turner DC, et al. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). J Neurooncol. 2015;123:85–91.
   PubMed Web of Science ®Google Scholar
• Gururangan S, Fangusaro J, Young Poussaint T, et al. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma–a pediatric brain tumor consortium study. Neuro-Oncol. 2012;14:1404–1412.
   PubMed Web of Science ®Google Scholar
• Atkinson JM, Shelat AA, Carcaboso AM, et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell. 2011;20:384–399.
   PubMed Web of Science ®Google Scholar
• Wright KD, Daryani VM, Turner DC, et al. Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro-Oncol. 2015;17:1620–1627.
   PubMed Web of Science ®Google Scholar
• Milde T, Kleber S, Korshunov A, et al. A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathol (Berl). 2011;122:637–650.
   PubMed Web of Science ®Google Scholar
• Peyre M, Commo F, Dantas-Barbosa C, et al. Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis. PloS One. 2010;5:e12932.
   Google Scholar
• Kong L-Y, Wei J, Haider AS, et al. Therapeutic targets in subependymoma. J Neuroimmunol. 2014;277:168–175.
   PubMed Web of Science ®Google Scholar
• Verma A, Zhou H, Chin S, et al. EGFR as a predictor of relapse in myxopapillary ependymoma. Pediatr Blood Cancer. 2012;59:746–748.
   PubMed Web of Science ®Google Scholar
• Mack SC, Agnihotri S, Bertrand KC, et al. Spinal myxopapillary ependymomas demonstrate a Warburg phenotype. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:3750–3758.
   Web of Science ®Google Scholar
• Gibson SE, Zeng WF, Weil RJ, et al. Aurora B kinase expression in ependymal neoplasms. Appl Immunohistochem Mol Morphol. 2008;16:274–278.
   PubMedGoogle Scholar
• Dantas-Barbosa C, Bergthold G, Daudigeos-Dubus E, et al. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors. Anticancer Drugs. 2015;26:272–283.
   PubMed Web of Science ®Google Scholar
• Rogers HA, Mayne C, Chapman RJ, et al. PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:6450–6460.
   Web of Science ®Google Scholar
• Korshunov A, Sycheva R, Timirgaz V, et al. Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases. J Neurooncol. 1999;45:219–227.
   PubMed Web of Science ®Google Scholar
• Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13:1663–1674.
   PubMed Web of Science ®Google Scholar
• Ginguene C, Champier J, Maallem S, et al. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas. Brain Pathol. 2010;20:926–935.
   PubMed Web of Science ®Google Scholar
• Grommes C, Oxnard GR, Kris MG, et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-Oncol. 2011;13:1364–1369.
   PubMed Web of Science ®Google Scholar
• Rajappa P, Krass J, Riina HA, et al. Super-selective basilar artery infusion of bevacizumab and cetuximab for multiply recurrent pediatric ependymoma. Interv Neuroradiol J Peritherapeutic Neuroradiol Surg Proced Relat Neurosci. 2011;17:459–465.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Filippi CG, Wong T, et al. Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study. J Neurooncol. 2016 Mar 5. [Epub ahead of print].
   Google Scholar
• Boockvar JA, Tsiouris AJ, Hofstetter CP, et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg. 2011;114:624–632.
   PubMed Web of Science ®Google Scholar
• Theeler BJ, Gilbert MR. Advances in the treatment of newly diagnosed glioblastoma. BMC Med. 2015;13:293.
   PubMed Web of Science ®Google Scholar
• Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncol. 2016;18(2):195–205.
   Google Scholar
• Fecci PE, Heimberger AB, Sampson JH. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20:5620–5629.
   PubMed Web of Science ®Google Scholar
• Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512:324–327.
   PubMed Web of Science ®Google Scholar
• Patel MA, Kim JE, Ruzevick J, et al. The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers. 2014;6:1953–1985.
   PubMed Web of Science ®Google Scholar
• Gerber NK, Young RJ, Barker CA, et al. Ipilimumab and whole brain radiation therapy for melanoma brain metastases. J Neurooncol. 2015;121:159–165.
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–1972.
   PubMed Web of Science ®Google Scholar
• Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16:e534–e542.
   PubMedGoogle Scholar